|
Rasner P.I., Al-Shukri A.S., Shormanov I.S., Tazhetdinov O.Kh., Maksimova A.V.
A multicenter, randomized, parallel, controlled, prospective, open-label study of the efficiency and safety of bovhyaluronidase azoximer in combination therapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia
|
№6 / 2024
|
|
D.V. Ergakov, A.G. Martov
New approaches to combined therapy of irritative symptoms in patients with benign prostatic hyperplasia
|
№2 / 2021
|
|
D.V. Ergakov, A.G. Martov
Paradigm shift in combination therapy during the COVID-19 pandemic
|
№1 / 2021
|
|
A.I. Neimark, A.V. Davydov, R.T. Aliev
The effects of combination therapy with 5α-reductase inhibitor and α-blocker on the prognosis of BPH
|
№2 / 2018
|
|
D.V. Ergakov, A.G. Martov
The Modern View of Conservative Therapy of Lower Urinary Tract Symptoms in Men
|
№5 / 2015
|
|
L.G. Spivak, K.L. Lokshin, A.Z. Vinarov
Review of Clinical Studies on Combination Therapy of 5α-Reductase Inhibitors and α1-Blockers in Patients with Benign Prostatic Hyperplasia
|
№4 / 2015
|
|
Z.K. Gadzhieva, Yu.B. Kazilov, Yu.G.Alyaev, I.A. Aboyan, B.R. Kazilov
Urination disorders. Do we know all about them?
|
№1 / 2014
|
|
Kamalov A.A., Osmolovsky B.E., Okhobotov D.A., Khodyreva L.A., Takhirzade T.B., Tahirzade A.M., Gevorkyan A.R.
Combined treatment of patients with erectile dysfunction and disorders of urination
|
№3 / 2013
|
Русский
